Current gene-encoded drug discovery approaches fall short of Pharma’s needs.
Unlike Curve’s Microcycle® platform, peptide display and DNA encoded libraries can only identify hits based on their strength of binding (affinity) to a purified and immobilised target.
Even if a biologically active compound can be found, the macrocycles that are discovered using peptide display technologies are far too large and unstructured for optimisation into therapeutics, in particular for intracellular targets such as protein-protein and protein-DNA interactions.
An evolving platform
Curve’s droplet microfluidic system is a next generation evolution of the platform that allows very high throughput and high efficiency functional screening and characterisation within a single femtolitre liquid droplet. This technology is protected by international patents and patent applications.
This microfluidics platform is being further developed to allow co-encapsulation of mammalian cells with a Microcycle® library within these droplets, enabling the discovery of functional hits against membrane proteins in their native conformation.
A platform built on strong foundations
Redefining Drug Discovery
Our vision is to redefine the discovery of first-in-class small molecule drugs by deploying our Microcycle® library and platform to broaden the landscape of addressable disease targets.